When was Avilar founded?

Avilar was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Avilar located?

Avilar is headquartered in Waltham, United States.

How many employees does Avilar have?

As of May 31, 2026, the latest employee count at Avilar is 24.

Is Avilar a funded company?

Avilar is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Dec 14, 2020.

When was the latest funding round of Avilar?

Avilar's latest funding was a $***** Seed round on Dec 14, 2020, with participation from 4 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $535M in funding in 2026 to date.

Where does Avilar rank among its competitors?

Avilar ranks 172nd amongst 594 active competitors, of which 207 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Avilar?

Avilar's top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Avilar - 2026 Company Profile, Team, Funding & Competitors

Avilar is a seed company based in Waltham (United States), founded in 2020 by Jesse Chen, James Kasuboski and Milind Deshpande. It operates as a Provider of drug discovery platform and protein degradation technology. Avilar has raised $75.3M in funding from investors like Astellas Venture Management, Sanofi Ventures and Medical Excellence Capital. The company has 594 active competitors, including 207 funded and 129 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.

Company Details

Provider of drug discovery platform and protein degradation technology. The company has built a proprietary technology platform to develop novel extracellular protein degraders called ATACs that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. It provides applications in a broad range of diseases.

Website: avilar-tx.com
Social

Key Metrics

Founded Year

2020

Location

Waltham, United States

Stage

Seed

Total Funding

$75.3M in 1 round

Latest Funding Round

Seed, Dec 14, 2020, $*****

Investors

Astellas Venture Management & 3 more

Ranked

172^nd among 594 active competitors

Employee Count

24 as on May 31, 2026

Similar Companies

Alnylam & 738 more

View Avilar's full profile

Avilar is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Avilar Therapeutics, Inc CIN: 84-3907227 , United States, Active	Dec 31, 2019	-	12 (As on Dec 31, 2021)	-
AVILAR THERAPEUTICS INC CIN: 843907227 , United States, Active	Dec 31, 1999	-	17 (As on Dec 31, 2024)	-

Avilar has raised a total funding of $75.3M over 1 round. Its latest funding round was a Seed round on Dec 14, 2020 for $*****. 4 investors participated in its latest round. Avilar has 4 institutional investors.

Here is the list of recent funding rounds of Avilar:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 14, 2020	4092677	Seed	3775259	8549555	6965071	3310923

Access funding benchmarks and valuations. Sign up today!

View details of Avilar's funding rounds and investors

The founders of Avilar are Jesse Chen, James Kasuboski and Milind Deshpande. Daniel Grau is the CEO of Avilar.

Here are the details of Avilar's key team members:

Jesse Chen: Co-Founder and Advisor of Avilar and founder of 1 other company.
James Kasuboski: Co-Founder of Avilar.
Milind Deshpande: Co-Founder of Avilar.
Daniel Grau: CEO of Avilar.
Contact Info: 1 email address

View details of Avilar's Founder profiles and Board Members

Avilar's employee count trend

Avilar has 24 employees as of May 26. Here is Avilar's employee count trend over the years:

Uncover Avilar's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avilar include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of Avilar, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Healthcap & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Danforth Advisors, Frazier Life Sciences & 2 others	67/100
172nd	Avilar 2020, Waltham (United States), Seed	Provider of drug discovery platform and protein degradation technology	$75.3M	RA Capital Management, Sanofi Ventures & 2 others	45/100